FG-4592 (Roxadustat)

Catalog No. A11237

FG-4592 (Roxadustat)是一种用于CKD贫血的新型缺氧诱导因子脯氨酰羟化酶抑制剂。

Product Citations

Singh C, .et al. Serine and 1-carbon metabolism are required for HIF-mediated protection against retinopathy of prematurity, JCI Insight, 2019, Jul 25;4(14) PMID: 31341109
Hideaki Nakamura, .et al. Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions, PLoS One, 2018, 13(2): e0192136 PMID: 29466367
Singh C, .et al. 3-Hydroxypyruvate Destabilizes Hypoxia Inducible Factor and Induces Angiostasis, Invest Ophthalmol Vis Sci, 2018, Jul 2;59(8):3440-3448 PMID: 30025089
George Hoppe, .et al. Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity, Proc Natl Acad Sci U S A, 2016, May 3; 113(18): E2516–E2525 PMID: 27091985

Technical details

Catalog Num	A11237
M. Wt	352.3
Formula	C19H16N2O5
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	808118-40-3
Synonyms	FG4592, ASP1517
SMILES	CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O

Biological Activity

FG-4592 (Roxadustat)是一种用于CKD贫血的新型缺氧诱导因子脯氨酰羟化酶抑制剂。

Targets

HIF α prolyl hydroxylase (Cell-free assay)

Solubility *

In vitro (25°C)	DMSO	62 mg/mL (175.96 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	9 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	28.38 mL	141.92 mL	283.85 mL
0.5 mM	5.68 mL	28.38 mL	56.77 mL
1 mM	2.84 mL	14.19 mL	28.38 mL
5 mM	0.57 mL	2.84 mL	5.68 mL

*The above data is based on the productmolecular weight 352.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.